Loading
Life sciences · Journal article
Cancer Research · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Vasculogenic mimicry (VM) is a process in which malignant cells acquire endothelial-like functions to generate perfusable vascular channels independent of endothelial cells. VM represents a major barrier to effective vascular endothelial growth factor A (VEGFA)-targeted therapy in cancer. In this study, we used organ-scale vascular imaging that identified a mechanism of VM in glioblastoma (GBM) mediated by alpha-L-fucosidase 1 (FUCA1). FUCA1 was preferentially expressed in glioblastoma stem-like cells (GSCs) with high CD44 expression. FUCA1 functioned as a key regulator of GSC-mediated VM by stabilizing LDHA protein and promoting a metabolic shift toward glycolysis. Elevated glycolytic flux increased lactate production and enhanced histone H3 lysine 18 lactylation (H3K18la), which in turn activated SERPINF1 transcription and drove VM in GSCs. In preclinical models, the FUCA1 inhibitor deoxyfuconojirimycin hydrochloride (DFH) significantly reduced GSC tumorigenicity and VM in vivo and exhibited robust antitumor activity when combined with anti-VEGFA therapy. Collectively, these findings define a FUCA1-mediated histone lactylation pathway that enhances GSC VM and highlight a therapeutically targetable mechanism to improve the efficacy of current anti-angiogenic strategies in GBM.